Advertisement

The management of childhood liver diseases in adulthood

Published:November 30, 2016DOI:https://doi.org/10.1016/j.jhep.2016.11.013

      Summary

      An increasing number of patients with childhood liver disease survive into adulthood. These young adults are now entering adult services and require ongoing management. Aetiologies can be divided into liver diseases that develop in young adults which present to adult hepatologists i.e., biliary atresia and Alagille syndrome or liver diseases that occur in children/adolescents and adults i.e., autoimmune hepatitis or Wilson’s disease. To successfully manage these young adults, a dynamic and responsive transition service is essential. In this review, we aim to describe the successful components of a transition service highlighting the importance of self-management support and a multi-disciplinary approach. We will also review some of the liver specific aetiologies which are unique to young adults, offering an update on pathogenesis, management and outcomes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McDonagh J.E.
        Growing up and moving on: transition from pediatric to adult care.
        Pediatr Transplant. 2005; 9: 364-372
        • Heldman M.R.
        • et al.
        National survey of adult transplant hepatologists on the pediatric-to-adult care transition after liver transplantation.
        Liver Transpl. 2015; 21: 213-223
        • Park M.J.
        • Paul Mulye T.
        • Adams S.H.
        • Brindis C.D.
        • Irwin Jr., C.E.
        The health status of young adults in the United States.
        J Adolesc Health. 2006; 39: 305-317
        • Sawyer S.M.
        • Blair S.
        • Bowes G.
        Chronic illness in adolescents: transfer or transition to adult services?.
        J Paediatr Child Health. 1997; 33: 88-90
        • Blum R.W.
        Transition from child-centered to adult health-care systems for adolescents with chronic conditions. A position paper of the Society for Adolescent Medicine.
        J Adolesc Health. 1993; 14: 570-576
        • Annunziato R.A.
        • et al.
        An empirically based practice perspective on the transition to adulthood for solid organ transplant recipients.
        Pediatr Transplant. 2014; 18: 794-802
        • Shemesh E.
        • et al.
        Medication adherence in pediatric and adolescent liver transplant recipients.
        Pediatrics. 2004; 113: 825-832
        • Kieckhefer G.M.
        • Trahms C.M.
        Supporting development of children with chronic conditions: from compliance toward shared management.
        Pediatr Nurs. 2000; 26: 354-363
        • Fredericks E.M.
        • et al.
        Assessment of transition readiness skills and adherence in pediatric liver transplant recipients.
        Pediatr Transplant. 2010; 14: 944-953
        • Chandra S.
        • Luetkemeyer S.
        • Romero R.
        • Gupta N.A.
        Growing up: not an easy transition-perspectives of patients and parents regarding transfer from a pediatric liver transplant center to adult care.
        Int J Hepatol. 2015; 2015765957
        • Bilhartz J.L.
        • et al.
        Assessing allocation of responsibility for health management in pediatric liver transplant recipients.
        Pediatr Transplant. 2015; 19: 538-546
        • Bell L.E.
        • et al.
        Adolescent transition to adult care in solid organ transplantation: a consensus conference report.
        Am J Transplant. 2008; 8: 2230-2242
        • Watson A.R.
        Problems and pitfalls of transition from paediatric to adult renal care.
        Pediatr Nephrol. 2005; 20: 113-117
        • Novak M.
        • Costantini L.
        • Schneider S.
        • Beanlands H.
        Approaches to self-management in chronic illness.
        Semin Dial. 2013; 26: 188-194
        • Kovacs A.H.
        • McCrindle B.W.
        So hard to say goodbye: transition from paediatric to adult cardiology care.
        Nat Rev Cardiol. 2014; 11: 51-62
        • Kaufman M.
        Transition of cognitively delayed adolescent organ transplant recipients to adult care.
        Pediatr Transplant. 2006; 10: 413-417
        • Vaks Y.
        • et al.
        Better health, less spending: Redesigning the transition from pediatric to adult healthcare for youth with chronic illness.
        Healthcare. 2016; 4: 57-68
        • Campbell F.
        • et al.
        Transition of care for adolescents from paediatric services to adult health services.
        Cochrane Database Syst Rev. 2016; 4: CD009794
        • Berquist R.K.
        • et al.
        Non-adherence to post-transplant care: prevalence, risk factors and outcomes in adolescent liver transplant recipients.
        Pediatr Transplant. 2008; 12: 194-200
        • Dobbels F.
        • Van Damme-Lombaert R.
        • Vanhaecke J.
        • De Geest S.
        Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients.
        Pediatr Transplant. 2005; 9: 381-390
        • Suris J.C.
        • Michaud P.A.
        • Viner R.
        The adolescent with a chronic condition. Part I: developmental issues.
        Arch Dis Child. 2004; 89: 938-942
        • Shaw R.J.
        • Palmer L.
        • Blasey C.
        • Sarwal M.
        A typology of non-adherence in pediatric renal transplant recipients.
        Pediatr Transplant. 2003; 7: 489-493
        • Fridell J.A.
        • et al.
        Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus.
        Transplantation. 2002; 74: 1721-1724
        • Beck D.E.
        • et al.
        Evaluation of an educational program on compliance with medication regimens in pediatric patients with renal transplants.
        J Pediatr. 1980; 96: 1094-1097
        • Jain A.
        • et al.
        The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
        Transplantation. 2003; 75: 1020-1025
        • Gagnadoux M.F.
        • Niaudet P.
        • Broyer M.
        Non-immunological risk factors in paediatric renal transplantation.
        Pediatr Nephrol. 1993; 7: 89-95
        • Watson A.R.
        Non-compliance and transfer from paediatric to adult transplant unit.
        Pediatr Nephrol. 2000; 14: 469-472
        • Sagar N.
        • et al.
        Pediatric liver transplant recipients who undergo transfer to the adult healthcare service have good long-term outcomes.
        Am J Transplant. 2015; 15: 1864-1873
        • De Geest S.
        • Sabate E.
        Adherence to long-term therapies: evidence for action.
        Eur J Cardiovasc Nurs. 2003; 2: 323
        • Blowey D.L.
        • et al.
        Compliance with cyclosporine in adolescent renal transplant recipients.
        Pediatr Nephrol. 1997; 11: 547-551
        • Meyers K.E.
        • Thomson P.D.
        • Weiland H.
        Noncompliance in children and adolescents after renal transplantation.
        Transplantation. 1996; 62: 186-189
        • Shemesh E.
        • et al.
        A pilot study of posttraumatic stress and nonadherence in pediatric liver transplant recipients.
        Pediatrics. 2000; 105: E29
        • Tucker C.M.
        • et al.
        Associations with medication adherence among ethnically different pediatric patients with renal transplants.
        Pediatr Nephrol. 2002; 17: 251-256
        • Fennell R.S.
        • Tucker C.
        • Pedersen T.
        Demographic and medical predictors of medication compliance among ethnically different pediatric renal transplant patients.
        Pediatr Transplant. 2001; 5: 343-348
        • Harden P.N.
        • et al.
        Bridging the gap: an integrated paediatric to adult clinical service for young adults with kidney failure.
        BMJ. 2012; 344e3718
        • European Association for the Study of the Liver
        EASL Clinical Practice Guidelines: Liver transplantation.
        J Hepatol. 2016; 64: 433-485
        • Joshi D.
        • James A.
        • Quaglia A.
        • Westbrook R.H.
        • Heneghan M.A.
        Liver disease in pregnancy.
        Lancet. 2010; 375: 594-605
        • Dommergues J.P.
        • et al.
        Current lifestyle of young adults after liver transplantation during childhood.
        Am J Transplant. 2010; 10: 1634-1642
        • Dhawan A.
        • Samyn M.
        • Joshi D.
        Young adults with paediatric liver disease: future challenges.
        Arch Dis Child. 2016; https://doi.org/10.1136/archdischild-2015-309580
        • Hartley J.L.
        • Davenport M.
        • Kelly D.A.
        Biliary atresia.
        Lancet. 2009; 374: 1704-1713
        • Davenport M.
        • et al.
        The biliary atresia splenic malformation syndrome: a 28-year single-center retrospective study.
        J Pediatr. 2006; 149: 393-400
        • Kasai M.
        Surgery of anomalies of the bile ducts, with special reference to surgical technics.
        Geka Chiryo. 1968; 19: 942-950
        • Barshes N.R.
        • et al.
        Orthotopic liver transplantation for biliary atresia: the U.S. experience.
        Liver Transpl. 2005; 11: 1193-1200
        • Fouquet V.
        • et al.
        Long-term outcome of pediatric liver transplantation for biliary atresia: a 10-year follow-up in a single center.
        Liver Transpl. 2005; 11: 152-160
        • Utterson E.C.
        • et al.
        Biliary atresia: clinical profiles, risk factors, and outcomes of 755 patients listed for liver transplantation.
        J Pediatr. 2005; 147: 180-185
        • Shneider B.L.
        • Mazariegos G.V.
        Biliary atresia: a transplant perspective.
        Liver Transpl. 2007; 13: 1482-1495
        • Matsuura T.
        • et al.
        A morphological study of the removed livers from patients receiving living donor liver transplantation for adult biliary atresia.
        Pediatr Surg Int. 2012; 28: 1171-1175
        • Takahashi A.
        • et al.
        Evidence for segmental bile drainage by hepatic portoenterostomy for biliary atresia: Cholangiographic, hepatic venographic, and histologic evaluation of the liver taken at liver transplantation.
        J Pediatr Surg. 2004; 39: 1-5
        • Lykavieris P.
        • et al.
        Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver.
        Hepatology. 2005; 41: 366-371
        • Chardot C.
        • et al.
        Improving outcomes of biliary atresia: French national series 1986–2009.
        J Hepatol. 2013; 58: 1209-1217
        • Altman R.P.
        • et al.
        A multivariable risk factor analysis of the portoenterostomy (Kasai) procedure for biliary atresia: twenty-five years of experience from two centers.
        Ann Surg. 1997; 226 ([Discussion 353–345]): 348-353
        • Shinkai M.
        • et al.
        Long-term outcome of children with biliary atresia who were not transplanted after the Kasai operation: >20-year experience at a children's hospital.
        J Pediatr Gastroenterol Nutr. 2009; 48: 443-450
        • de Vries W.
        • et al.
        Twenty-year transplant-free survival rate among patients with biliary atresia.
        Clin Gastroenterol Hepatol. 2011; 9: 1086-1091
        • Nio M.
        • et al.
        Five- and 10-year survival rates after surgery for biliary atresia: a report from the Japanese Biliary Atresia Registry.
        J Pediatr Surg. 2003; 38: 997-1000
        • Thabut D.
        • et al.
        Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding.
        Hepatology. 2015; 61: 1024-1032
        • Ng V.L.
        • et al.
        Medical status of 219 children with biliary atresia surviving long-term with their native livers: results from a North American multicenter consortium.
        J Pediatr. 2014; 165: 539-546e532
        • Bijl E.J.
        • Bharwani K.D.
        • Houwen R.H.
        • de Man R.A.
        The long-term outcome of the Kasai operation in patients with biliary atresia: a systematic review.
        Neth J Med. 2013; 71: 170-173
        • Hadzic N.
        • et al.
        Hepatocellular carcinoma in biliary atresia: King's College Hospital experience.
        J Pediatr. 2011; 159: 617-622e611
        • Jacquemin E.
        Progressive familial intrahepatic cholestasis.
        Clin Res Hepatol Gastroenterol. 2012; 36: S26-S35
        • Davit-Spraul A.
        • Gonzales E.
        • Baussan C.
        • Jacquemin E.
        Progressive familial intrahepatic cholestasis.
        Orphanet J Rare Dis. 2009; 4: 1
        • Alvarez L.
        • et al.
        Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1.
        Hum Mol Genet. 2004; 13: 2451-2460
        • Chen F.
        • et al.
        Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity.
        Gastroenterology. 2004; 126: 756-764
        • Strautnieks S.S.
        • et al.
        Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24.
        Am J Hum Genet. 1997; 61: 630-633
        • Bull L.N.
        • et al.
        A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis.
        Nat Genet. 1998; 18: 219-224
        • Strautnieks S.S.
        • et al.
        A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis.
        Nat Genet. 1998; 20: 233-238
        • Sambrotta M.
        • et al.
        Mutations in TJP2 cause progressive cholestatic liver disease.
        Nat Genet. 2014; 46: 326-328
        • Davit-Spraul A.
        • et al.
        ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history.
        Hepatology. 2010; 51: 1645-1655
        • Jacquemin E.
        • et al.
        Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.
        Hepatology. 1997; 25: 519-523
        • European Association for the Study of the Liver
        EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
        J Hepatol. 2009; 51: 237-267
        • Bustorff-Silva J.
        • et al.
        Partial internal biliary diversion through a cholecystojejunocolonic anastomosis–a novel surgical approach for patients with progressive familial intrahepatic cholestasis: a preliminary report.
        J Pediatr Surg. 2007; 42: 1337-1340
        • Stapelbroek J.M.
        • et al.
        Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis.
        Hepatology. 2006; 43: 51-53
        • Miyagawa-Hayashino A.
        • et al.
        Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation.
        Liver Transpl. 2009; 15: 610-618
        • Gonzales E.
        • Jacquemin E.
        Mutation specific drug therapy for progressive familial or benign recurrent intrahepatic cholestasis: a new tool in a near future?.
        J Hepatol. 2010; 53: 385-387
        • Knisely A.S.
        • et al.
        Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency.
        Hepatology. 2006; 44: 478-486
        • Li L.
        • et al.
        Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1.
        Nat Genet. 1997; 16: 243-251
        • Alagille D.
        • et al.
        Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases.
        J Pediatr. 1987; 110: 195-200
        • Kamath B.M.
        • et al.
        A longitudinal study to identify laboratory predictors of liver disease outcome in Alagille syndrome.
        J Pediatr Gastroenterol Nutr. 2010; 50: 526-530
        • Lykavieris P.
        • Hadchouel M.
        • Chardot C.
        • Bernard O.
        Outcome of liver disease in children with Alagille syndrome: a study of 163 patients.
        Gut. 2001; 49: 431-435
        • Kamath B.M.
        • Schwarz K.B.
        • Hadzic N.
        Alagille syndrome and liver transplantation.
        J Pediatr Gastroenterol Nutr. 2010; 50: 11-15
        • Qu D.
        • Teckman J.H.
        • Perlmutter D.H.
        Review: alpha 1-antitrypsin deficiency associated liver disease.
        J Gastroenterol Hepatol. 1997; 12: 404-416
        • Perlmutter D.H.
        Alpha-1-antitrypsin deficiency: diagnosis and treatment.
        Clin Liver Dis. 2004; 8: 839-859
        • Perlmutter D.H.
        Clinical manifestations of alpha 1-antitrypsin deficiency.
        Gastroenterol Clin North Am. 1995; 24: 27-43
        • Sveger T.
        Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants.
        N Engl J Med. 1976; 294: 1316-1321
        • Mieli-Vergani G.
        • Vergani D.
        Autoimmune hepatitis.
        Nat Rev Gastroenterol Hepatol. 2011; 8: 320-329
        • Deneau M.
        • et al.
        Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history.
        Hepatology. 2013; 58: 1392-1400
        • Vitfell-Pedersen J.
        • Jorgensen M.H.
        • Muller K.
        • Heilmann C.
        Autoimmune hepatitis in children in Eastern Denmark.
        J Pediatr Gastroenterol Nutr. 2012; 55: 376-379
        • Gregorio G.V.
        • et al.
        Autoimmune hepatitis in childhood: a 20-year experience.
        Hepatology. 1997; 25: 541-547
        • Martini E.
        • et al.
        Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2.
        Hepatology. 1988; 8: 1662-1666
        • Gregorio G.V.
        • et al.
        Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study.
        Hepatology. 2001; 33: 544-553
        • Maggiore G.
        • et al.
        Treatment of autoimmune chronic active hepatitis in childhood.
        J Pediatr. 1984; 104: 839-844
        • Maggiore G.
        • et al.
        Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents.
        J Pediatr Gastroenterol Nutr. 1993; 17: 376-381
        • Al-Chalabi T.
        • Underhill J.A.
        • Portmann B.C.
        • McFarlane I.G.
        • Heneghan M.A.
        Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis.
        J Hepatol. 2008; 48: 140-147
        • Al-Chalabi T.
        • Underhill J.A.
        • Portmann B.C.
        • McFarlane I.G.
        • Heneghan M.A.
        Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome.
        Clin Gastroenterol Hepatol. 2008; 6 ([Quiz 1287]): 1389-1395
        • Kirstein M.M.
        • et al.
        Prediction of short- and long-term outcome in patients with autoimmune hepatitis.
        Hepatology. 2015; 62: 1524-1535
        • Ngu J.H.
        • Gearry R.B.
        • Frampton C.M.
        • Stedman C.A.
        Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study.
        Hepatology. 2013; 57: 2399-2406
        • European Association for the Study of the Liver
        EASL clinical practice guidelines: autoimmune hepatitis.
        J Hepatol. 2015; 63: 971-1004
        • Alvarez F.
        • et al.
        International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.
        J Hepatol. 1999; 31: 929-938
        • Ebbeson R.L.
        • Schreiber R.A.
        Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful?.
        Clin Gastroenterol Hepatol. 2004; 2: 935-940
        • Rumbo C.
        • Emerick K.M.
        • Emre S.
        • Shneider B.L.
        Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report.
        J Pediatr Gastroenterol Nutr. 2002; 35: 391-398
        • Manns M.P.
        • et al.
        Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.
        Gastroenterology. 2010; 139: 1198-1206
        • Manns M.P.
        • et al.
        Diagnosis and management of autoimmune hepatitis.
        Hepatology. 2010; 51: 2193-2213
        • Heneghan M.A.
        • McFarlane I.G.
        Current and novel immunosuppressive therapy for autoimmune hepatitis.
        Hepatology. 2002; 35: 7-13
        • Sciveres M.
        • Caprai S.
        • Palla G.
        • Ughi C.
        • Maggiore G.
        Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents.
        Aliment Pharmacol Ther. 2004; 19: 209-217
        • Aqel B.A.
        • et al.
        Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis.
        J Clin Gastroenterol. 2004; 38: 805-809
        • Tannous M.M.
        • et al.
        Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience.
        Aliment Pharmacol Ther. 2011; 34: 405-407
        • Czaja A.J.
        Autoimmune hepatitis in diverse ethnic populations and geographical regions.
        Expert Rev Gastroenterol Hepatol. 2013; 7: 365-385
        • Heneghan M.A.
        • Yeoman A.D.
        • Verma S.
        • Smith A.D.
        • Longhi M.S.
        Autoimmune hepatitis.
        Lancet. 2013; 382: 1433-1444
        • Deneau M.
        • Book L.S.
        • Guthery S.L.
        • Jensen M.K.
        Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis: a population-based study.
        J Pediatr. 2014; 164: 714-719e712
        • Czaja A.J.
        • Menon K.V.
        • Carpenter H.A.
        Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.
        Hepatology. 2002; 35: 890-897
        • van Gerven N.M.
        • et al.
        Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands.
        Scand J Gastroenterol. 2014; 49: 1245-1254
        • Czaja A.J.
        • Ludwig J.
        • Baggenstoss A.H.
        • Wolf A.
        Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis.
        N Engl J Med. 1981; 304: 5-9
        • Czaja A.J.
        • Beaver S.J.
        • Shiels M.T.
        Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis.
        Gastroenterology. 1987; 92: 215-219
        • Liberal R.
        • Longhi M.S.
        • Grant C.R.
        • Mieli-Vergani G.
        • Vergani D.
        Autoimmune hepatitis after liver transplantation.
        Clin Gastroenterol Hepatol. 2012; 10: 346-353
        • Ogden C.L.
        • Carroll M.D.
        • Kit B.K.
        • Flegal K.M.
        Prevalence of childhood and adult obesity in the United States, 2011–2012.
        JAMA. 2014; 311: 806-814
        • Schwimmer J.B.
        • McGreal N.
        • Deutsch R.
        • Finegold M.J.
        • Lavine J.E.
        Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents.
        Pediatrics. 2005; 115: e561-e565
        • Schwimmer J.B.
        • et al.
        Prevalence of fatty liver in children and adolescents.
        Pediatrics. 2006; 118: 1388-1393
        • Schenk S.
        • Saberi M.
        • Olefsky J.M.
        Insulin sensitivity: modulation by nutrients and inflammation.
        J Clin Invest. 2008; 118: 2992-3002
        • Polyzos S.A.
        • Kountouras J.
        • Zavos C.
        • Tsiaousi E.
        The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
        Diabetes Obes Metab. 2010; 12: 365-383
        • Takaki A.
        • Kawai D.
        • Yamamoto K.
        Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH).
        Int J Mol Sci. 2014; 15: 7352-7379
        • Lake A.D.
        • et al.
        The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease.
        Toxicol Sci. 2014; 137: 26-35
        • Friedman S.L.
        Mechanisms of hepatic fibrogenesis.
        Gastroenterology. 2008; 134: 1655-1669
        • Zhu L.
        • et al.
        Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.
        Hepatology. 2013; 57: 601-609
        • Moore J.B.
        • Gunn P.J.
        • Fielding B.A.
        The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease.
        Nutrients. 2014; 6: 5679-5703
        • Romeo S.
        • et al.
        Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
        Nat Genet. 2008; 40: 1461-1465
        • Sookoian S.
        • Pirola C.J.
        Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.
        Hepatology. 2011; 53: 1883-1894
        • Valenti L.
        • et al.
        Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
        Hepatology. 2010; 51: 1209-1217
        • Liu Y.L.
        • et al.
        Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
        J Hepatol. 2014; 61: 75-81
        • Nobili V.
        • et al.
        Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.
        Hepatology. 2008; 48: 119-128
        • Lavine J.E.
        • et al.
        Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.
        JAMA. 2011; 305: 1659-1668
        • Neuschwander-Tetri B.A.
        • et al.
        Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
        Lancet. 2015; 385: 956-965
        • Nobili V.
        • et al.
        Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN Hepatology Committee Position Statement.
        J Pediatr Gastroenterol Nutr. 2015; 60: 550-561
        • Tao T.Y.
        • Gitlin J.D.
        Hepatic copper metabolism: insights from genetic disease.
        Hepatology. 2003; 37: 1241-1247
        • European Association for Study of Liver
        EASL Clinical Practice Guidelines: Wilson's disease.
        J Hepatol. 2012; 56: 671-685